Drug resistance to topoisomerase II inhibitors

Biochimie

Volumn 80, Issue 3, 1998, Pages 247-254

  Robert, J ^a   Larsen, A K ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Drug resistance; Topoisomerase II; Tumors

Indexed keywords

AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; GYRASE INHIBITOR; MITOXANTRONE; TENIPOSIDE;

CELL LINE; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; GENE MUTATION; HUMAN; REVIEW;

EID: 0032033345     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(98)80007-2     Document Type: Article

References (71)

1. 1 Watt PM, Hickson ID (1994) Structure and function of type II DNA topoisomerases. Biochem J 303, 681-695
2. 2 Wang JC (1995) DNA topoisomerases. Annu Rev Biochem 54, 665-697
3. 3 Andersen AH, Svejstrup JQ, Westergaard O (1994) The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerase I and topoisomerase II. Adv Pharmacol 29A, 83-101
4. 4 Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232
5. 5 Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58, 351-375
6. 6 Corbett AH, Osheroff N (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6, 585-597
7. 7 Wang JC (1994) DNA topoisomerases as targets of therapeutics. An overview. Adv Pharmacol 29A, 1-19
8. 8 Chen AY, Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34, 191-218
9. 9 Walker BP, Smith C, Youndale T, Leblanc J, Whitfield JF, Sikorska M (1991) Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51, 1078-1085
10. 10 Nitiss JL, Liu YX, Hsiung Y (1993) A temperature-sensitive topoisomerase II allele confers temperature-dependent drug resistance on amsacrine and etoposide. A genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53, 89-93
11. 11 Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID, Gatter K, Harris AL (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75, 1340-1346
12. 12 Gottesman MM, Pastan I (1993) Biochemistry of mukidrug resistance mediated by the multidrug transporter. Annu Rev Bochem 62, 385-427
13. 13 Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of 'atypical' multidrug resistant human leukemic cells. Cancer Res 47, 5455-5460
14. 14 De Isabella P, Capranico G, Zunino F (1991) The role of topoisomerase II in drug resistance. Life Sci 48, 2195-2205
15. 15 Beck WT, Danks MK, Wolverton S, Chen M, Granzen B Kim R, Suttle DP (1994) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 29B, 145-169
16. 16 Hochhauser D, Harris AL (1993) The role of DNA topoisomerase II α and β in drug resistance. Cancer Treat Rev 19, 181-194
17. 17 Vassetzky YS, Alghisi GC, Gasser SM (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays 17, 767-774
18. 18 Prost S (1995) Mechanisms of resistance to topoisomerase poisons. Gen Pharmacol 26,1773-1774
19. 19 Deffie AM, Bosman DJ, Goldenberg GJ (1989) Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49, 6879-6882
20. 20 Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81, 1732-1735
21. 21 Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49, 58-62
22. 22 Takano H, Kohno K, Ono M, Uchida Y, Kuwano M (1991) Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51, 3951-3957
23. 23 Khélifa T, Casabianca-Pignède MR, René B, Jacquemin-Sablon A (1994) Expression of topoisomerases IIα and β in Chinese hamster cells resistant to topoisomerase II inhibitors. Mol Pharmacol 46, 323-332
24. 24 Matsuo KI, Kohno K, Takano H, Sato SI, Kiue A, Kuwano M (1990) Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 50, 5819-5824
25. 25 Evans CD, Mirski SEL, Danks MK, Cole SPC (1994) Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung cancer cell line. Cancer Chemother Pharmacol 34, 242-248
26. 26 Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R (1996) Reduced expression of DNA topoisomerase II confers resistance to etoposide in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol Res 8, 229-238
27. 27 Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48, 5956-596
28. 28 Lefevre D, Riou JF, Ahomadegbe JC, Zhou D, Benard J, Riou G (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S-transferase. Biochem Pharmacol 41, 1967-1979
29. 29 Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA (1995) Drastic reduction of topoisomerase IIα associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Oncol Res 7, 407-416
30. 30 Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC (1994) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer 69, 687-697
31. 31 Prost S, Riou G (1994) A human small celt lung carcinoma cell line, resistant to m-AMSA and cross-resistant to camptothecin with a high level of topoisomerase I. Biochem Pharmacol 48, 975-984
32. 32 Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM (1994) Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 54, 756-762
33. 33 Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH (1995) Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55, 1707-1716
34. 34 Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA, Capranico G (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerase IIα (P170) and IIβ (P180). Mol Pharmacol 50, 1463-1471
35. 35 Corbett AH, Fernald AW, Osheroff N (1993) Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis. Evidence for a common mechanism of regulation by phosphorylation. Biochemistry 32, 2090-2097
36. 36 Dereuddre S, Frey S, Delaporte C, Jacquemin-Sablon A (1995) Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase IIβ from Chinese hamster lung cells sensitive and resistant to 9-OH-ellipticine. Biochim Biophys Acta 1264, 178-182
37. 37 Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, Krivacic K (1996) Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. MoL Pharmacol 50, 243-248
38. II protein kinase C. Mol Pharmacol 48, 798-805
39. r 160 000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55, 2129-2134
40. 40 Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51, 4729-4731
41. 41 Bugg BY, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88 7654-7658
42. r 170 000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53, 1373-1379
43. 43 Chan VTW, Ng SW, Eder JP, Schipper LE (1993) Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem 268, 2160-2165
44. 44 Patel S, Fisher LM (1993) Novel selection and genetic characterisation of an etoposide-resistant human leukemic CCRF-CEM cell line. Br J Cancer 67, 456-463
45. 45 Campain JA, Gottesman MM, Pastan I (1994) A novel mutant topoisomerase II α present in VP- 16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 33, 11327-11332
46. 46 Lee MS, Wang JC, Beran M (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223, 837-843
47. 47 Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA (1995) A novel point mutation in the 3′ flanking region of the DNA-binding domain of topoisomerase IIα associated with acquired resistance to topoisomerase II active agents. Oncol Res 7, 21-29
48. 48 Danks MK, Schmidt CA, Deneka DA, Beck WT (1989) Increased ATP requirement for activity and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide. Cancer Commun 1, 101-109
49. 49 Hsiung Y, Jannatipour M, Rose A, McMahon J, Duncan D, Nitiss JL (1996) Functional expression of topoisomerase IIα in yeast: mutation-s at amino acids 450 or 803 of topoisomerase II α results in enzymes that can confer resistance to antitopoisomerase II agents. Cancer Res 56, 91-99
50. 50 Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ (1995) Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55, 78-82
51. 51 Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, Hickson ID (1995) Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72, 1454-1461
52. 52 Sano K, Shuhin T (1995) A study of topoisomerase activity in human testicular cancers. Anticancer Res 15, 2117-2120
53. 53 Shuin T, Sano K (1994) The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma. Anticancer Res 14, 2621-2626
54. 54 Volm M, Kästel M, Mattern J, Efferth T (1993) Expression of resistance factors (P-glycoprotein, glutathione S-transferase π, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71, 3981-397
55. 55 Davies SL, Popert R, Copcoat M, Hickson ID, Masters JRW (1996) Response to epirubicin in patients with superficial bladder cancer and expression of topoisomerase IIα and β genes. Int J Cancer 65, 63-66
56. 56 van der Zee AGJ, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG, de Vries EGE (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51, 5915-5920
57. 57 Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL (1996) Differential expression of the topoisomerase IIα and β genes in human breast cancers. Br J Cancer 73, 1518-1524
58. 58 Hellemans P, van Dam PA, Geyskens M, van Oosterom AT, Buytaert P, van Marck E (1995) Immunohistochemical study of topoisomerase II α expression in primary ductal carcinoma of the breast. J Clin Pathol 48, 147-150
59. 59 Guinee DG, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, Travis WD (1996) Comparison of DNA topoisomerase IIα expression in small cell and non-small cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 78, 729-735
60. 60 Gekeler V, Frese G, Noller A, Handgretinger R, Wilisch A, Schmidt H, Muller CP, Dopfer R, Klingebiel T, Diddens H, Probst H, Niethammer D (1992) MDR1/P-glycoprotein, topoisomerase, and glutathione S-transferase π gene expression in primary and relapsed state adult and childhood leukemias. Br J Cancer 66, 507-517
61. 61 Klumper E, Giaccone G, Pieters R, Broekema G, van Ark-Otte J, van Wering ER, Kaspers GJL, Veerman AJP (1995) Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia 9, 1653-1660
62. 62 Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V (1995) Expression of MDR1, MRP, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89, 356-363
63. 63 Gieseler F, Glasmacher A, Kämpfe D, Wandt H, Nuessler V, Valsamas S, Kunze J, Wilms K (1996) Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxins. Leukemia 10, 1177-1180
64. 64 McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA (1994) Topoisomerase II α expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 8, 1498-1502
65. 65 Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ (1994) Topoisomerase II levels and drug sensitivity in acute myelogenous leukemia. Blood 83, 517-530
66. 66 Beck J, Niethammer D, Gekeler V (1996) MDR1, MRP, topoisomerase IIα/b, and cyclin A gene expression in acute and chronic leukemias. Leukemia 10 suppl 3, S39-S45
67. 67 Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K (1991) Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11, 429-432
68. 68 McLeod HL, Douglas F, Oates M, Symonds RP, van der Zee AGJ, Kaye SB, Brown R, Keith WN (1994) Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59, 607-611
69. 69 Eijdems EWHM, de Haas M, Timmerman AJ, van der Schans GP, Kamst E, de Nooij J, Astalsi Ricotti GCB, Borst P, Baas F (1995) Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer 71, 40-47
70. 70 Danks MK, Beck WT, Suttle DP (1993) Topoisomerase IIα mutation in leukemic cells from a patient with lineage switch AML. Proc Am Assoc Cancer Res 34, 333
71. 71 Kubo A, Yoshikawa A, Hirashima T, Masuda N, Takada M, Takahara J, Fukuoka M, Nakagawa K (1996) Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide. Cancer Res 56, 1232-1236